Mirroring this therapeutic promise, our animal osteomyelitis model showed that MEK1 inhibition markedly attenuated bone destruction scores, underscoring its dual mechanism of action—simultaneously curbing bacterial persistence and preserving bone integrity. The gene discussed is MAP2K1; the disease is osteomyelitis.